An implantable cardiac monitor with an alert system was safe for patients with prior acute coronary syndromes (ACS) but failed to significantly reduce primary-endpoint events compared to the control group, according to late-breaking trial results presented Sunday at Cardiovascular Research Technologies (CRT) 2019.